The recall stems from abnormal endotoxin results in certain samples, which could lead to serious systemic reactions and ...

Since the start of the month, several drug recalls have entered the FDA’s periphery, affecting products ranging from hospital ...

Fresenius Kabi issues voluntary nationwide recall of three lots of Famotidine injection due to out-of-specification endotoxin results: Lake Zurich Friday, November 14, 2025, 10:00 ...

Fresenius Kabi recalls lots of famotidine injection vials due to elevated endotoxin levels posing sepsis risk, per FDA alert.

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

The Food and Drug Administration Nov. 8 announced it is investigating an outbreak of 13 infant botulism illnesses in 10 ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Get the latest on Atea Pharmaceuticals’ Q3 2025 earnings, HCV Phase III progress, hepatitis E pipeline expansion, and key financial updates.

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected ...

Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,100 subjects at daily doses ...

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...

Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q3 earnings call. Read on for the main highlights of the call. Atea Pharmaceuticals’ recent ...